Antiangiogenic Therapy for Metastatic Breast Cancer

摘要: The use of chemotherapy and endocrine therapy have led to objective tumour shrinkage improved survival in women with metastatic breast cancer. Despite the availability many chemotherapeutic drugs, these agents do not act specifically on various growth signalling pathways that drive progression. This lack specificity is likely explain inconsistent responses seen across population cancer patients contributes undesirable adverse effects. expanding knowledge important molecular involved tumourogenesis progression has exciting development several classes targeted agents. potential advantage such treatment improve cell kill less damage healthy tissues. Hormonal were first utilize specific estrogen receptor-related for therapeutic efficacy. Agents directed human epidermal factor receptor (HER)-2/neu pathway exemplify effectiveness new generation biological agents, but are limited 20-25% cancers overexpress receptor. However, angiogenesis a critical component necessary all subset cancers. Therefore, can diminish or prevent far broader application benefit Several anti-angiogenic been evaluated phase I, II III trials These demonstrated efficacy when used combination toxicity profile better defined. Issues regarding mechanisms resistance, identifying regimens result greatest clinical benefits minimizing effects areas require further research.